Halpern, Harhay, Saulsgiver, Brophy, Troxel, and Volpp set out to discover “whether financial incentives, pharmacologic therapies, and electronic cigarettes promote smoking cessation among unselected smokers”.
They write: “We randomly assigned smokers employed by 54 companies to one of four smoking-cessation interventions or to usual care. Usual care consisted of access to information regarding the benefits of smoking cessation and to a motivational text-messaging service.”
So far so good.
The four interventions tested:
- Free cessation aids (NRT products or quit medicine, plus ecigs NRT/pills failed)
- Free e-cigarettes, without a requirement that standard therapies had been tried
- Free cessation aids plus $600 in rewards for sustained abstinence
- Free cessation aids plus $600 that could be taken back if the smokers didn’t remain quitters for six months.
The team claim to have discovered that from 6,006 subjects, “sustained abstinence rates through 6 months were 0.1% in the usual-care group, 0.5% in the free cessation aids group, 1.0% in the free e-cigarettes group, 2.0% in the rewards group, and 2.9% in the redeemable deposit group”.
This all seems very clear cut and supports the team in stating that offering financial incentives was more successful than smokers being able to vape – even if vaping was twice as successful as the traditional quit products.
The team gleefully state that their work has “several strengths”. This might be good news for employers looking to help employees quit smoking, the NEJM having another opportunity to bash vaping – or maybe offering Simon Chapman and Stanton Glantz something else to tweet about?
What is clear is the single, very major flaw in the entire proceedings: vaping works when the smoker can successfully substitute cigarettes for something that delivers nicotine successfully.
Poor quality, out-dated products haven’t worked for smokers - the research team used cigalikes, a poor nicotine delivery vehicle to begin with, that contained just 10-15mg of nicotine, an insufficient level for long-term smokers using this type of device.
No doubt this study will go on to be quoted, but its glaring error means that they found out nothing regarding the efficacy of vaping products – just that poor cigalikes as twice as good for quitters than traditional Pharma nicotine replacement products.
Dave Cross
Journalist at POTVDave is a freelance writer; with articles on music, motorbikes, football, pop-science, vaping and tobacco harm reduction in Sounds, Melody Maker, UBG, AWoL, Bike, When Saturday Comes, Vape News Magazine, and syndicated across the Johnston Press group. He was published in an anthology of “Greatest Football Writing”, but still believes this was a mistake. Dave contributes sketches to comedy shows and used to co-host a radio sketch show. He’s worked with numerous start-ups to develop content for their websites.
Join the discussion
Parliament Fears Two
The Department for Environment, Food and Rural Affairs faced questions from a Conservative MP and, oddly, a member of the Department for Environment, Food and Rural Affairs
Harm Reduction For The Rich
The United Kingdom risks becoming a harm reduction country only for the wealthy, according to Michael Landl of the World Vapers’ Alliance
Sacrificing Health For 2p Cut
Tory Government alienates vaping voters with its mission to cut tax by an unaffordable 2p to attract voters by placing a tax on vape products in the forthcoming budget
Scotland Announces Single-Use Vape Action
A ban on the sale and supply of single-use vapes in Scotland is due to come into effect on 1 April 2025, under proposed legislation published today